MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Sorrento Therapeutics DPO Ratio 2011-2026 | SRNE
Annual DPO Ratio Sorrento Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 907 | 824 | 613 | 842 | 2.17 K | 280 | 340 | 118 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 118 K | 280 | 15.5 K |
Quarterly DPO Ratio Sorrento Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 550 | 563 | - | 569 | 705 | 659 | - | 951 | 1.19 K | 853 | - | 633 | 1.17 K | 569 | - | 309 | 634 | 317 | - | 239 | 218 | 270 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 K | 218 | 612 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.69 | 2.74 % | $ 198 M | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
4.06 K | $ 31.56 | 2.29 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |  Britain |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.74 | 3.46 % | $ 256 M |  Israel |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
981 | $ 0.76 | 11.14 % | $ 34.7 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 32.33 | 3.32 % | $ 870 M | USA |
 |
Affimed N.V.
AFMD
|
2.52 K | - | -34.95 % | $ 21.5 M |  Germany |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | Israel |
 |
Hutchison China MediTech Limited
HCM
|
47.8 | $ 11.68 | -0.6 % | $ 10 B | China |
 |
Heron Therapeutics
HRTX
|
91.4 | $ 0.91 | 3.18 % | $ 152 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | USA |
 |
ImmuCell Corporation
ICCC
|
12.3 | $ 10.49 | -0.1 % | $ 94.7 M | USA |
 |
Anika Therapeutics
ANIK
|
43.4 | $ 14.72 | -1.12 % | $ 211 M | USA |
 |
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |